EDIT – Editas Medicine, Inc.
Editas Medicine, Inc.EDIT
$2.42Name : Editas Medicine, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $373,301,536.00
EPSttm : -0.54
Editas Medicine, Inc.
$2.42
3.45%$0.086
EDIT — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
27.56
Margin Of Safety %
Put/Call OI Ratio
0.18
EPS Next Q Diff
EPS Last/This Y
0.97
EPS This/Next Y
0.08
Price
2.5
Target Price
5.11
Analyst Recom
2
Performance Q
-11.8
Upside
-643.4%
Beta
2.07
Ticker: EDIT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | EDIT | 2.73 | 0.29 | 0.07 | 29958 |
| 2026-10-13 | EDIT | 2.44 | 0.29 | 0.40 | 30067 |
| 2026-10-14 | EDIT | 2.27 | 0.29 | 0.34 | 30422 |
| 2026-10-15 | EDIT | 2.43 | 0.27 | 0.07 | 30444 |
| 2026-10-16 | EDIT | 2.36 | 0.29 | 2.62 | 29796 |
| 2026-10-19 | EDIT | 2.42 | 0.19 | 0.09 | 26635 |
| 2026-10-20 | EDIT | 2.58 | 0.19 | 0.03 | 27207 |
| 2026-10-21 | EDIT | 2.51 | 0.17 | 0.04 | 29271 |
| 2026-10-22 | EDIT | 2.48 | 0.18 | 0.00 | 29242 |
| 2026-10-23 | EDIT | 2.38 | 0.18 | 0.78 | 29249 |
| 2026-10-26 | EDIT | 2.4 | 0.18 | 0.02 | 29323 |
| 2026-10-27 | EDIT | 2.61 | 0.17 | 0.02 | 29357 |
| 2026-10-28 | EDIT | 2.94 | 0.17 | 0.16 | 29402 |
| 2026-10-29 | EDIT | 2.92 | 0.18 | 0.01 | 29192 |
| 2026-10-30 | EDIT | 2.66 | 0.18 | 0.07 | 29154 |
| 2026-11-02 | EDIT | 2.57 | 0.18 | 0.25 | 29144 |
| 2026-11-03 | EDIT | 2.62 | 0.18 | 0.69 | 29066 |
| 2026-11-04 | EDIT | 2.74 | 0.18 | 1.30 | 29087 |
| 2026-11-05 | EDIT | 2.54 | 0.18 | 0.93 | 29134 |
| 2026-11-06 | EDIT | 2.57 | 0.18 | 1.44 | 29279 |
| 2026-11-09 | EDIT | 2.76 | 0.18 | 0.01 | 29329 |
| 2026-11-10 | EDIT | 2.51 | 0.18 | 1.80 | 29278 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | EDIT | 2.75 | 26.4 | - | -0.83 |
| 2026-10-13 | EDIT | 2.45 | 26.4 | - | -0.83 |
| 2026-10-14 | EDIT | 2.27 | 26.4 | - | -0.83 |
| 2026-10-15 | EDIT | 2.43 | 26.4 | - | -0.83 |
| 2026-10-16 | EDIT | 2.36 | 26.4 | - | -0.83 |
| 2026-10-19 | EDIT | 2.42 | 26.4 | - | -0.83 |
| 2026-10-20 | EDIT | 2.42 | 26.4 | - | -0.83 |
| 2026-10-21 | EDIT | 2.58 | 26.4 | - | -0.83 |
| 2026-10-22 | EDIT | 2.48 | 26.4 | - | -0.83 |
| 2026-10-23 | EDIT | 2.38 | 26.4 | - | -0.83 |
| 2026-10-26 | EDIT | 2.40 | 26.4 | - | -0.83 |
| 2026-10-27 | EDIT | 2.61 | 26.4 | - | -0.83 |
| 2026-10-28 | EDIT | 2.95 | 26.4 | - | -0.83 |
| 2026-10-29 | EDIT | 2.93 | 26.4 | - | -0.83 |
| 2026-10-30 | EDIT | 2.66 | 26.4 | - | -0.83 |
| 2026-11-02 | EDIT | 2.57 | 26.4 | - | -0.83 |
| 2026-11-03 | EDIT | 2.62 | 26.4 | - | -0.83 |
| 2026-11-04 | EDIT | 2.74 | 26.4 | - | -0.83 |
| 2026-11-05 | EDIT | 2.53 | 26.4 | - | -0.83 |
| 2026-11-06 | EDIT | 2.56 | 26.4 | - | -0.83 |
| 2026-11-09 | EDIT | 2.76 | 26.4 | - | -0.83 |
| 2026-11-10 | EDIT | 2.50 | 26.4 | - | -0.83 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | EDIT | -0.19 | 22.85 | 26.79 |
| 2026-10-13 | EDIT | -0.19 | 22.85 | 26.79 |
| 2026-10-14 | EDIT | -0.19 | 22.85 | 26.79 |
| 2026-10-15 | EDIT | -0.19 | 22.85 | 26.79 |
| 2026-10-16 | EDIT | -0.19 | 22.85 | 26.79 |
| 2026-10-19 | EDIT | -0.19 | 22.67 | 26.79 |
| 2026-10-20 | EDIT | -0.19 | 22.67 | 26.79 |
| 2026-10-21 | EDIT | -0.19 | 22.67 | 26.79 |
| 2026-10-22 | EDIT | -0.19 | 22.67 | 26.79 |
| 2026-10-23 | EDIT | -0.19 | 22.67 | 26.79 |
| 2026-10-26 | EDIT | -0.19 | 22.51 | 26.79 |
| 2026-10-27 | EDIT | -0.19 | 22.51 | 27.56 |
| 2026-10-28 | EDIT | -0.19 | 22.51 | 27.56 |
| 2026-10-29 | EDIT | -0.19 | 22.51 | 27.56 |
| 2026-10-30 | EDIT | -0.19 | 22.51 | 27.56 |
| 2026-11-02 | EDIT | -0.19 | 22.34 | 27.56 |
| 2026-11-03 | EDIT | -0.19 | 22.34 | 27.56 |
| 2026-11-05 | EDIT | -0.19 | 22.34 | 27.56 |
| 2026-11-06 | EDIT | -0.19 | 22.34 | 27.56 |
| 2026-11-09 | EDIT | -0.19 | 19.43 | 27.56 |
| 2026-11-10 | EDIT | -0.19 | 19.43 | 27.56 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.21
Avg. EPS Est. Next Quarter
-0.21
Insider Transactions
-0.19
Institutional Transactions
19.43
Beta
2.07
Average Sales Estimate Current Quarter
4
Average Sales Estimate Next Quarter
6
Fair Value
Quality Score
29
Growth Score
34
Sentiment Score
60
Actual DrawDown %
94
Max Drawdown 5-Year %
-97.6
Target Price
5.11
P/E
Forward P/E
PEG
P/S
7.72
P/B
4.55
P/Free Cash Flow
EPS
-0.62
Average EPS Est. Cur. Y
-0.83
EPS Next Y. (Est.)
-0.75
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-144.95
Relative Volume
0.58
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-92
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.17
EBIT Estimation
◆
EDIT
Healthcare
$2.51
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
46.2
Range 1M
36.8%
Sup Dist
0%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
58.5%
EPS NY
7.2%
52W%
37.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+103.6% upside
Upside
+103.6%
Quality
29
EDIT — P/E HistoricalBiotechnology
Editas Medicine, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 87
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
EDIT
Latest News
—
Caricamento notizie per EDIT…
stock quote shares EDIT – Editas Medicine, Inc. Stock Price stock today
news today EDIT – Editas Medicine, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch EDIT – Editas Medicine, Inc. yahoo finance google finance
stock history EDIT – Editas Medicine, Inc. invest stock market
stock prices EDIT premarket after hours
ticker EDIT fair value insiders trading